Methodological concerns regarding "Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials"
Global Cardiology Science and Practice · 30.10.2026 · 2026 (5)
DOI: 10.21542/gcsp.2026.44 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 30.10.2026. Verfasst von Dayyan Ahmad Muazzam und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
[No abstract, showing first paragraph of letter] Dear Editor, We read with interest the meta-analysis by Ahmed et al. evaluating vutrisiran in transthyretin amyloidosis (ATTR) [1]. While the review addresses a clinically important question, we wish to raise several methodological concerns not addressed in the manuscript's limitations section.
Zitieren
APA
Muazzam, D. A., & Sajid, H. (2026). Methodological concerns regarding "Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials". Global Cardiology Science and Practice, 2026(5). https://doi.org/10.21542/gcsp.2026.44
Vancouver
Muazzam DA, Sajid H. Methodological concerns regarding "Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials". Global Cardiology Science and Practice. 2026;2026(5). doi:10.21542/gcsp.2026.44
BibTeX
@article{Muazzam2026,
author = {Muazzam, Dayyan Ahmad and Sajid, Hamza},
title = {Methodological concerns regarding "Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials"},
journal = {Global Cardiology Science and Practice},
year = {2026},
volume = {2026},
number = {5},
doi = {10.21542/gcsp.2026.44}
}
EUVIMED